Cargando…
Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)
Autores principales: | Rockstroh, J, Felizarta, F, Maggiolo, F, Pulido, F, Stellbrink, HJ, Tsybakova, O, Yeni, P, Almond, S, Brothers, C, Song, I, Min, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The International AIDS Society
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112866/ http://dx.doi.org/10.1186/1758-2652-13-S4-O50 |
Ejemplares similares
-
Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010) -
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
por: Stellbrink, Hans-Jürgen, et al.
Publicado: (2013) -
Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials
por: Jiang, Junjun, et al.
Publicado: (2016) -
Among once-daily regimens, single tablet regimens (STRs) are associated with better adherence
por: Murri, R, et al.
Publicado: (2012) -
Archibald Inglis
Publicado: (1889)